PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Frost & Sullivan

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Frost & Sullivan Recognizes MIV Therapeutics for Technological Breakthroughs in Interventional Cardiology Enabled by its HAp-based Drug Delivery Sys - Frost & Sullivan recognizes MIV Therapeutics, Inc. (OTC/BB: MIVT) (Frankfurt: MIV), a leading developer of next-generation coatings and advanced drug delivery systems for cardiovascular stents and other implantable medical devices
Frost & Sullivan Recognizes MIV Therapeutics for Technological Breakthroughs in Interventional Cardiology Enabled by its HAp-based Drug Delivery Sys

 

NewswireToday - /newswire/ - Palo Alto, CA, United States, 2008/03/13 - Frost & Sullivan recognizes MIV Therapeutics, Inc. (OTC/BB: MIVT) (Frankfurt: MIV), a leading developer of next-generation coatings and advanced drug delivery systems for cardiovascular stents and other implantable medical devices.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Medical Services/Equipment Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Based on its recent analysis of the interventional cardiology markets, Frost & Sullivan recognizes MIV Therapeutics, Inc. (OTC/BB: MIVT) (Frankfurt: MIV), a leading developer of next-generation coatings and advanced drug delivery systems for cardiovascular stents and other implantable medical devices,. with the 2008 North American Frost & Sullivan Award for Technology Innovation.

This Award recognizes MIV Therapeutics’ development of next generation coatings and drug delivery systems based on hydroxyapatite (HAp) for cardiac stents and other implantable medical devices.

“MIV Therapeutics’ HAp-based drug delivery systems are completely polymer-free and made from naturally occurring materials making them unique in addressing the limitations of commonly used polymeric coatings and polymeric drug delivery systems,” says Frost & Sullivan Research Analyst Pramodh Ishwarakrishnan. “Animals and human studies performed thus far indicate that HAp-based coatings are safe, effective in delivering drug, and do not induce thrombogenic, allergic or inflammatory reactions seen with polymers, making them strong candidates for future medical device applications.”

In collaboration with The University of British Columbia (UBC), MIV Therapeutics has developed two HAp coatings that range in thickness from 100 to 500 nanometers.

The first is non-porous and can be used as a biocompatible surface coating to protect the surrounding tissue from potential side effects caused by metals used in implantable medical devices.

The second is porous and can be used as a biocompatible surface coating capable of delivering drug to local tissue. The company's lead product incorporating this novel technology is a drug eluting stent (DES) aimed at addressing the drawbacks of the currently available DES and is in early human testing.

“DES safety is drawing much scrutiny as the events of restenosis, late stage thrombosis (the formation of blood clots) and death are now exceeding those seen with bare-metal stents (BMS) – despite the original evidence as demonstrated in clinical trials that DES are as safe as their BMS counterparts,” notes Ishwarakrishnan. “Correspondingly, the global use of DES has plummeted and in many countries the use of BMS exceeds the use of DES.”

One other serious limitation of current DES is the need for patients to comply with a long-term antiplatelet regimen to prevent the formation of blood clots and late stage thrombosis. Antiplatelet therapy severely hampers the ability to provide future medical and dental treatment to patients who are taking them as they reduce the patient’s ability to clot and increase the risk of severe bleeding.

To address these limitations, MIV Therapeutics has developed a new DES, the VESTAsync™, which has demonstrated excellent safety and efficacy profiles in trials. The VESTAsync is polymer-free, combining nanothin microporous HAp with low dose sirolimus in a proprietary formulation.

VESTAsync has an ultra thin drug coating which, at 600 nanometers, is over 10 times thinner than any drug coating currently found on today’s drug eluting stent‘s. When compared to the competition, VESTAsync shows superior healing, lower inflammation, 75 percent less fibrinoid deposition (a marker of delayed healing) and early efficacy results that are comparable to currently FDA approved DES. These results are strong reinforcement’s of MIV Therapeutics’ strategy to bring to market a DES with the safety profile of a BMS, requiring BMS-like antiplatelet therapy.

“The company holds an exclusive license to the intellectual property (IP) that was originally developed at UBC, which covers the HAp surface modification available on the stent and also some of the formulations that are used to load the drug” adds Ishwarakrishnan.

In summary, the surface modifications and drug delivery systems based on HAp show excellent biocompatibility, flexibility, deliverability and optimal drug delivery compared to the first and second generation polymer-based DES.

For developing a completely polymer-free approach to tackling the present day limitations of the first and second generation stents, Frost & Sullivan is proud to present MIV Therapeutics with the 2008 North American Technology Innovation Award in the field of interventional cardiology.

Each year Frost & Sullivan presents this Award to the company that has carried out new research, which has resulted in innovation(s) that have or are expected to bring significant contributions to the industry in terms of adoption, change, and competitive posture. The Award recognizes the quality and depth of a company’s research and development program as well as the vision and risk-taking that enabled it to undertake such an endeavor.

Frost & Sullivan Best Practices Awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research in order to identify best practices in the industry.

About Frost & Sullivan

Frost & Sullivan, the Global Growth Consulting Company, partners with clients to accelerate their growth. The company's Growth Partnership Services, Growth Consulting and Career Best Practices empower clients to create a growth-focused culture that generates, evaluates and implements effective growth strategies. Frost & Sullivan employs over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 30 offices on six continents.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Medical Services/Equipment Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Frost & Sullivan

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 
 
  Your Banner Ad showing on ALL
Medical Services/Equipment articles,
CATCH Visitors via Your Competitors Announcements!


Frost & Sullivan Recognizes MIV Therapeutics for Technological Breakthroughs in Interventional Cardiology Enabled by its HAp-based Drug Delivery Sys

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

Frost & Sullivan |
Publisher Contact: Stacie Kopecki 
210.247.2450 Stacie.kopecki[.]frost.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Frost & Sullivan securities in any jurisdiction including any other companies listed or named in this release.

Medical Services/Equipment via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Frost & Sullivan / Company Profile


Read Medical Services/Equipment Most Recent Related Newswires:

Sparta Systems Broadens Partnership with TrackWise Implementation Specialist Equality Systems
Thales Launches the Pixium Portable 3543 DR Wifi Enabled Flat Panel Detector
GE Healthcare Showcases Industry-first Technologies and Digital Solutions, Focused on Improving Outcomes, At RSNA 2016
Agfa and LCsys Team Up to Launch ABSOLUT-ID, Their Turnkey Integrated Solution for the Production of High Security ID Cards
ZOLL Technology for Improving CPR Quality to be Showcased at American Heart Association Annual Conference
AccuVein to Exhibit Leading Vein Visualization Technology at American Society for Dermatologic Surgery Annual Meeting
US Biomedical Textiles Transform Implant Device Technology by Aligning to Changes in Patient Preference Finds Frost & Sullivan
Frost & Sullivan Commends Influence Health for Constantly Evolving its Patient Engagement Products to Accelerate Market Transformation
Frost & Sullivan Awards Carestream Top Honors for OnSight 3D Extremity System
Sparta Systems Launches the Next-Generation Cloud Solution Stratas QMS
Koning Wins Accolades from Frost & Sullivan for the Impressive Innovation Behind its Groundbreaking KBCT Breast Imaging Device
Frost & Sullivan Awards ResMed for Developing S+ Advanced Sleep Tracking System
Sparta Systems Becomes First Quality Management Solutions Provider to Achieve EU-U.S. Privacy Shield Compliance
ZOLL Expands the Rescuer Experience at EMS World Expo
Agfa and GPMI Sign Distribution Agreement for Agfa’s Synthetic Paper Synaps

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  BizJobs.com

Visit  Triggr & Bloom





 
  ©2016 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)